Legislation on child-safe medicine set to roll out

Odriscoll, Cath
June 2006
ICIS Chemical Business;6/12/2006, Vol. 1 Issue 23, p47
Trade Publication
This article focuses on a new medical legislation in Europe. More than 50% of medicines used to treat children in Europe remain untested and unauthorised for used in children, severely restricting the choice of drugs prescribed by doctors. The new legislation is intended to change this, by introducing a package of measures obliging pharmaceutical companies to present the results of clinical trials that involve children at the time of applying for drug authorisation.


Related Articles

  • "Bonne Année", "Gutes Neues Johr"? Will 2007 be a "Happy New Year" for children's medicines in Europe? Stephenson, T. // Archives of Disease in Childhood;Aug2007, Vol. 92 Issue 8, p661 

    The article discusses a new European Union (EU) pediatric legislation, which focuses on encouraging more research on pediatric medicines. The legislation's proposals include incentives to encourage pharmaceutical industries to test products for use in children and the establishment of a...

  • Research & Markets: Clinical Trials Market in Russia - Out Now!  // Biomedical Market Newsletter;5/17/2011, p572 

    The article focuses on the report entitled "Clinical Trials Market in Russia" which has been added to the offerings of Research & Market Ltd.. It says that the country spends in drug research & development (R&D) process which attracts clinical trials. It mentions the issues that comprises...

  • Cross Over NOW. Lazarus, Ian // Pharmaceutical Executive;Jul2001, Vol. 21 Issue 7, p66 

    Focuses on the clinical research organization (CRO) industry and the growing interdependence among pharmaceutical companies, research organizations, and technology suppliers. Benefits of automating clinical trials; Market potential of the CRO; Factors affecting drug development. INSET:...

  • Clinical Trial Listings and Results Go Public. Wechsler, Jill // Applied Clinical Trials;Oct2004, Vol. 13 Issue 10, p22 

    Reports on the disclosure initiatives undertaken by pharmaceutical companies to better inform the public about opportunities to participate in clinical trials and drug research data results in the U.S. Reaction of the sponsors to pressure to register ongoing clinical trials and to provide access...

  • Drug studies in developing countries. Olliaro, Piero L.; Vijayan, Ramani; Inbasegaran, K.; Chim Choy Lang; Looareesuwan, Sornchai // Bulletin of the World Health Organization;2001, Vol. 79 Issue 9, p894 

    Discusses the status of drug studies in developing countries. Dependence of research and development to pharmaceutical industry of industrialized countries; Lack of necessity for administration of clinical trials; Absence of system for chemical entities by regulatory authorities.

  • The Virtual Revolution (The Time Is Now). Scheible, Lee S.; Pozsgai, Michael A. // Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p32 

    Reports on the capability of virtual tools and processes to decrease pharmaceutical research and development costs. Advantages of the virtual training process in any clinical trials; Establishment of a secure document access and delivery process in compliance with 21 CFR 11 and internal security...

  • Knowing When to Pull the Plug On Your Experimental Drug. Lam, Michael D. // Pharmaceutical Executive;Feb2004, Vol. 24 Issue 2, p54 

    Focuses on the problems faced by the pharmaceutical industry in the U.S. Failures in the process of drug development; Concern of companies about the declining research and development productivity; Cost of the clinical trials for the drugs.

  • Achieving Operational Excellence. Bhat, Ashok // Pharmaceutical Processing;Aug2011, Vol. 26 Issue 7, p32 

    The article offers tips for pharmaceutical companies on the integration of drugs related clinical research into their operations. It explains the use of patient randomization management and treatment allocation as the first step towards integration and discusses the benefits of automating...

  • Change of purpose.  // Nature;5/20/2010, Vol. 465 Issue 7296, p267 

    The article focuses on the repurposing of existing drugs. It mentions that when a drug was no longer protected by patents, it was difficult for a pharmaceutical company to reimburse the investment to test the drug. It states that several solutions on the issue have been proposed such as the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics